China-based Phrontline Biopharma has raised nearly USD 40 million in a Series A led by Oriza Seed and Decheng Capital, with Jifeng Ventures, Lapam Capital, Songqing Private Equity Fund, C&D Emerging Capital and Med-Fine Capital joining, following a USD 60 million Pre-A+ round in 2025 that takes cumulative financing close to USD 100 million. Funds will advance clinical development of core assets, push differentiated pipeline candidates toward IND filing, build new payload platforms and support international partnerships and capital-market preparation.
Founded in early 2022, Phrontline is among China's earliest developers focused on bispecific ADCs and dual-payload ADCs, with a full-stack platform spanning antibody engineering, linker-payload chemistry and functional evaluation across topo1i, microtubule, DNA-alkylator, ATR, NMT and pan-RAS inhibitor mechanisms.
Lead asset TJ101, an EGFR×B7-H3 bispecific ADC, showed encouraging activity across NSCLC, SCLC, prostate and urothelial tumours in a Phase Ia readout, while TJ102, a first-in-class FRα×CDH6 bispecific dual-payload ADC, became the first programme of its kind to enter the clinic after preclinical synergy data, giving Phrontline a differentiated position against conventional single-payload ADC competition.

Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation